{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:39:15Z","timestamp":1792744755873,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["T4-AN-04"],"award-info":[{"award-number":["T4-AN-04"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"DOI":"10.1007\/s40290-026-00640-y","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:01:23Z","timestamp":1792742483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ataxia Therapeutics: A Comprehensive Overview of the Clinical Development Pipeline"],"prefix":"10.1007","author":[{"given":"Marisa","family":"Cappella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Locuratolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Polizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vanacore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Lacorte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Piscopo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"640_CR1","doi-asserted-by":"publisher","unstructured":"Hafiz S, Jesus O De. Ataxia. Encyclopedia of movement disorders, three-volume set [Internet]. StatPearls Publishing; 2023 [cited 2025 Jun 5];V1-70\u2013V1-86. https:\/\/doi.org\/10.1016\/B978-0-12-374105-9.00153-2.","DOI":"10.1016\/B978-0-12-374105-9.00153-2"},{"key":"640_CR2","doi-asserted-by":"publisher","unstructured":"Fogel BL, Perlman S. An approach to the patient with late-onset cerebellar ataxia. Nat Clin Pract Neurol [Internet]. 2006 [cited 2026 Apr 22];2:629\u201335. https:\/\/doi.org\/10.1038\/NCPNEURO0319.","DOI":"10.1038\/NCPNEURO0319"},{"key":"640_CR3","doi-asserted-by":"publisher","unstructured":"Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primers. 2019;5:24. https:\/\/doi.org\/10.1038\/S41572-019-0074-3.","DOI":"10.1038\/S41572-019-0074-3"},{"key":"640_CR4","doi-asserted-by":"publisher","unstructured":"Klockgether T, Paulson H. Milestones in ataxia. Mov Disord [Internet]. 2011 [cited 2025 Oct 2];26:1134. https:\/\/doi.org\/10.1002\/MDS.23559.","DOI":"10.1002\/MDS.23559"},{"key":"640_CR5","doi-asserted-by":"publisher","unstructured":"Lacorte E, Piscopo P, Sagliocca L, Vignatelli L, Taruscio D, Vanacore N, et al. The National Italian Guidelines on the diagnosis and treatment of children with pediatric ataxias. Front Neurol. 2022;13:971781. https:\/\/doi.org\/10.3389\/FNEUR.2022.971781\/TEXT.","DOI":"10.3389\/FNEUR.2022.971781\/TEXT"},{"key":"640_CR6","doi-asserted-by":"publisher","unstructured":"Kwei KT, Kuo SH. An overview of the current state and the future of ataxia treatments. Neurol Clin [Internet]. 2020 [cited 2025 Sep 30];38:449\u201367. https:\/\/doi.org\/10.1016\/J.NCL.2020.01.008.","DOI":"10.1016\/J.NCL.2020.01.008"},{"key":"640_CR7","doi-asserted-by":"publisher","unstructured":"Rossi M, Stephen CD, Dam\u00e1sio J, Pedroso JL, Kuo SH, Lin CYR, et al. Unravelling the global tapestry of genetic ataxias: epidemiology and genetic testing approaches. Mov Disord [Internet]. 2025 [cited 2025 Oct 2];40:1805\u201320. https:\/\/doi.org\/10.1002\/MDS.30302.","DOI":"10.1002\/MDS.30302"},{"key":"640_CR8","doi-asserted-by":"publisher","unstructured":"Buesch K, Zhang R. A systematic review of disease prevalence, health-related quality of life, and economic outcomes associated with Friedreich\u2019s Ataxia. Curr Med Res Opin [Internet]. 2022 [cited 2025 Oct 2];38:1739\u201349. https:\/\/doi.org\/10.1080\/03007995.2022.2112870.","DOI":"10.1080\/03007995.2022.2112870"},{"key":"640_CR9","doi-asserted-by":"publisher","unstructured":"Labuda M, Labuda D, Miranda C, Poirier J, Soong BW, Barucha NE, et al. Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion. Neurology [Internet]. 2000 [cited 2025 Oct 2];54:2322\u20134. https:\/\/doi.org\/10.1212\/WNL.54.12.2322.","DOI":"10.1212\/WNL.54.12.2322"},{"key":"640_CR10","doi-asserted-by":"publisher","unstructured":"Klockgether T. Sporadic adult-onset ataxia. Handb Clin Neurol [Internet]. 2018 [cited 2025 Oct 2];155:217\u201325. https:\/\/doi.org\/10.1016\/B978-0-444-64189-2.00014-7.","DOI":"10.1016\/B978-0-444-64189-2.00014-7"},{"key":"640_CR11","doi-asserted-by":"publisher","unstructured":"Rummey C, Corben LA, Delatycki MB, Subramony SH, Bushara K, Gomez CM, et al. Psychometric properties of the Friedreich Ataxia Rating Scale. Neurol Genet [Internet]. 2019 [cited 2025 Oct 6];5:371. https:\/\/doi.org\/10.1212\/NXG.0000000000000371.","DOI":"10.1212\/NXG.0000000000000371"},{"key":"640_CR12","doi-asserted-by":"publisher","unstructured":"Schmitz-H\u00fcbsch T, Du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology [Internet]. 2006 [cited 2025 Oct 6];66:1717\u201320. https:\/\/doi.org\/10.1212\/01.WNL.0000219042.60538.92.","DOI":"10.1212\/01.WNL.0000219042.60538.92"},{"key":"640_CR13","doi-asserted-by":"publisher","unstructured":"Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci [Internet]. 1997 [cited 2025 Oct 6];145:205\u201311. https:\/\/doi.org\/10.1016\/S0022-510X(96)00231-6.","DOI":"10.1016\/S0022-510X(96)00231-6"},{"key":"640_CR14","doi-asserted-by":"publisher","unstructured":"Brandsma R, Spits AH, Kuiper MJ, Lunsing RJ, Burger H, Kremer HP, et al. Ataxia rating scales are age-dependent in healthy children. Dev Med Child Neurol [Internet]. 2014 [cited 2026 Apr 27];56:556\u201363. https:\/\/doi.org\/10.1111\/DMCN.12369.","DOI":"10.1111\/DMCN.12369"},{"key":"640_CR15","doi-asserted-by":"publisher","unstructured":"Lawerman TF, Brandsma R, Burger H, Burgerhof JGM, Sival DA. Age-related reference values for the pediatric Scale for Assessment and Rating of Ataxia: a multicentre study. Dev Med Child Neurol [Internet]. 2017 [cited 2026 Apr 27];59:1077\u201382. https:\/\/doi.org\/10.1111\/DMCN.13507;SUBPAGE:STRING:FULL.","DOI":"10.1111\/DMCN.13507;SUBPAGE:STRING:FULL"},{"key":"640_CR16","doi-asserted-by":"publisher","unstructured":"Knudson KC, Gupta AS. Assessing cerebellar disorders with wearable inertial sensor data using time-frequency and autoregressive hidden Markov model approaches. Sensors (Basel) [Internet]. 2022 [cited 2026 Apr 27];22:9454. https:\/\/doi.org\/10.3390\/S22239454.","DOI":"10.3390\/S22239454"},{"key":"640_CR17","doi-asserted-by":"publisher","unstructured":"Ngo T, Pathirana PN, Horne MK, Corben LA, Harding IH, Szmulewicz DJ. Technological evolution in the instrumentation of ataxia severity measurement. IEEE Access [Internet]. 2023 [cited 2026 Apr 27];11:14006\u201327. https:\/\/doi.org\/10.1109\/ACCESS.2023.3243178.","DOI":"10.1109\/ACCESS.2023.3243178"},{"key":"640_CR18","doi-asserted-by":"publisher","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). Ann Neurol [Internet]. 2021 [cited 2025 Sep 30];89:212\u201325. https:\/\/doi.org\/10.1002\/ANA.25934.","DOI":"10.1002\/ANA.25934"},{"key":"640_CR19","doi-asserted-by":"publisher","unstructured":"Boesch S, Indelicato E. Approval of omaveloxolone for Friedreich ataxia. Nat Rev Neurol [Internet]. Nature Research; 2024 [cited 2025 Sep 30];20:313\u20134. https:\/\/doi.org\/10.1038\/S41582-024-00957-9;SUBJMETA.","DOI":"10.1038\/S41582-024-00957-9;SUBJMETA"},{"key":"640_CR20","doi-asserted-by":"publisher","unstructured":"Refolo LM, Snyder H, Liggins C, Ryan L, Silverberg N, Petanceska S, et al. Common Alzheimer\u2019s disease research ontology: National Institute on Aging and Alzheimer\u2019s Association collaborative project. Alzheimers and Dement [Internet]. 2012 [cited 2025 Jun 6];8:372\u20135. https:\/\/doi.org\/10.1016\/J.JALZ.2012.05.2115.","DOI":"10.1016\/J.JALZ.2012.05.2115"},{"key":"640_CR21","unstructured":"Zolgensma\u00ae\u2014Cure SMA. https:\/\/www.curesma.org\/ [Internet]. [cited 2025 Oct 6]. https:\/\/www.curesma.org\/zolgensma\/. Accessed 6 Oct 2025."},{"key":"640_CR22","unstructured":"SGT-212\u2014Friedreich\u2019s Ataxia Research Alliance [Internet]. [cited 2025 Oct 22]. https:\/\/www.curefa.org\/drug-development\/sgt-212\/. Accessed 22 Oct 2025."},{"key":"640_CR23","doi-asserted-by":"publisher","unstructured":"Munoz-Zuluaga C, Gertz M, Yost-Bido M, Greco A, Gorman N, Chen A, et al. Identification of safe and effective intravenous dose of AAVrh.10hFXN to treat the cardiac manifestations of Friedreich\u2019s ataxia. Hum Gene Ther [Internet]. 2023 [cited 2025 Oct 8];34:605\u201315. https:\/\/doi.org\/10.1089\/HUM.2023.020.","DOI":"10.1089\/HUM.2023.020"},{"key":"640_CR24","unstructured":"Design therapeutics announces start of Friedreich ataxia patient dosing ex-U.S. in its RESTORE-FA phase 1\/2 multiple-ascending dose trial of DT-216P2 | Design Therapeutics, Inc [Internet]. [cited 2025 Oct 8]. https:\/\/investors.designtx.com\/news-releases\/news-release-details\/design-therapeutics-announces-start-friedreich-ataxia-patient. Accessed 8 Oct 2025."},{"key":"640_CR25","unstructured":"Letter to the FA Community from Astellas Pharma\u2014Friedreich\u2019s ataxia research alliance [Internet]. [cited 2025 Oct 8]. https:\/\/www.curefa.org\/news\/letter-to-the-fa-community-from-astellas-pharma-feb-2025\/. Accessed 8 Oct 2025."},{"key":"640_CR26","unstructured":"Interim update from Vico Therapeutics on their CAG-targeting drug, VO659\u2014HDBuzz [Internet]. [cited 2025 Oct 8]. https:\/\/en.hdbuzz.net\/398\/. Accessed 8 Oct 2025."},{"key":"640_CR27","unstructured":"Biogen Reports First Quarter 2023 Results | Biogen [Internet]. [cited 2025 Oct 8]. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-reports-first-quarter-2023-results. Accessed 8 Oct 2025."},{"key":"640_CR28","doi-asserted-by":"publisher","unstructured":"Bhartiya M, Kumar A, Singh RK, Radhakrishnan DM, Rajan R, Srivastava AK. Mesenchymal stem cell therapy in the treatment of neurodegenerative cerebellar ataxias: a systematic review and meta-analysis. Cerebellum [Internet]. 2023 [cited 2025 Oct 6];22:363\u20139. https:\/\/doi.org\/10.1007\/S12311-022-01403-6.","DOI":"10.1007\/S12311-022-01403-6"},{"key":"640_CR29","doi-asserted-by":"publisher","unstructured":"Baile MG, Jones J, Sahr N, Shankar G. Nomlabofusp, a fusion protein of human frataxin and a cell penetrant peptide, delivers mature and functional frataxin into mitochondria. AAPS J. 2025;27:68. https:\/\/doi.org\/10.1208\/S12248-025-01054-5.","DOI":"10.1208\/S12248-025-01054-5"},{"key":"640_CR30","doi-asserted-by":"publisher","unstructured":"Shirakura T, Krishnamoorthy L, Paliwal P, Hird G, McCluskie K, McWilliams P, et al. In vitro treatment with liposome-encapsulated Mannose-1-phosphate restores N-glycosylation in PMM2-CDG patient-derived fibroblasts. Mol Genet Metab. 2024;143:108531. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108531.","DOI":"10.1016\/j.ymgme.2024.108531"},{"key":"640_CR31","doi-asserted-by":"publisher","unstructured":"Budhraja R, Radenkovic S, Jain A, Muffels IJJ, Ismaili MHA, Kozicz T, et al. Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation. Mol Genet Metab. 2024;142. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108487.","DOI":"10.1016\/j.ymgme.2024.108487"},{"key":"640_CR32","unstructured":"N-Acetyl-L-Leucine reduces disease progression in phase 2 extension study for ataxia-telangiectasia | NeurologyLive\u2014Clinical Neurology News and Neurology Expert Insights [Internet]. [cited 2025 Oct 8]. https:\/\/www.neurologylive.com\/view\/n-acetyl-l-leucine-reduces-disease-progression-phase-2-extension-study-ataxia-telangiectasia. Accessed 8 Oct 2025."},{"key":"640_CR33","doi-asserted-by":"publisher","unstructured":"Feil K, Adrion C, Boesch S, Doss S, Giordano I, Hengel H, et al. Safety and efficacy of acetyl-dl-leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial. JAMA Netw Open [Internet]. 2021 [cited 2025 Oct 20];4:E2135841. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2021.35841.","DOI":"10.1001\/JAMANETWORKOPEN.2021.35841"},{"key":"640_CR34","doi-asserted-by":"publisher","unstructured":"Strupp M, Muth C, Mansmann U. Fampridine and acetazolamide for the treatment of episodic ataxia type 2 (EAT2TREAT): a randomised, double-blind, placebo-controlled, three-period crossover trial (2331). Neurology [Internet]. 2020 [cited 2025 Oct 8];94:2331. https:\/\/doi.org\/10.1212\/WNL.94.15_SUPPLEMENT.2331.","DOI":"10.1212\/WNL.94.15_SUPPLEMENT.2331"},{"key":"640_CR35","doi-asserted-by":"publisher","unstructured":"Muth C, Teufel J, Schols L, Synofzik M, Franke C, Timmann D, et al. Fampridine and acetazolamide in EA2 and related familial EA: a prospective randomized placebo-controlled trial. Neurol Clin Pract [Internet]. 2021 [cited 2025 Oct 8];11:e438. https:\/\/doi.org\/10.1212\/CPJ.0000000000001017.","DOI":"10.1212\/CPJ.0000000000001017"},{"key":"640_CR36","doi-asserted-by":"publisher","unstructured":"Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2002;(2):CD001447. https:\/\/doi.org\/10.1002\/14651858.CD001447.","DOI":"10.1002\/14651858.CD001447"},{"key":"640_CR37","doi-asserted-by":"publisher","unstructured":"Romano S, Coarelli G, Marcotulli C, Leonardi L, Piccolo F, Spadaro M, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol [Internet]. 2015 [cited 2025 Sep 24];14:985\u201391. https:\/\/doi.org\/10.1016\/S1474-4422(15)00201-X.","DOI":"10.1016\/S1474-4422(15)00201-X"},{"key":"640_CR38","doi-asserted-by":"publisher","unstructured":"Coarelli G, Heinzmann A, Ewenczyk C, Fischer C, Chupin M, Monin ML, et al. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol [Internet]. 2022 [cited 2025 Sep 24];21:225\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(21)00457-9.","DOI":"10.1016\/S1474-4422(21)00457-9"},{"key":"640_CR39","doi-asserted-by":"publisher","unstructured":"Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology [Internet]. 2012 [cited 2026 Apr 22];78:545\u201350. https:\/\/doi.org\/10.1212\/WNL.0B013E318247CC7A;REQUESTEDJOURNAL:JOURNAL:WNL;JOURNAL:JOURNAL:WNL;WGROUP:STRING:PUBLICATION.","DOI":"10.1212\/WNL.0B013E318247CC7A;REQUESTEDJOURNAL:JOURNAL:WNL;JOURNAL:JOURNAL:WNL;WGROUP:STRING:PUBLICATION"},{"key":"640_CR40","doi-asserted-by":"publisher","unstructured":"Seritan AL, Nguyen DV, Mu Y, Tassone F, Bourgeois JA, Schneider A, et al. Memantine for fragile X-associated tremor\/ataxia syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry [Internet]. 2014 [cited 2025 Sep 24];75:264\u201371. https:\/\/doi.org\/10.4088\/JCP.13M08546.","DOI":"10.4088\/JCP.13M08546"},{"key":"640_CR41","doi-asserted-by":"publisher","unstructured":"Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. J Neurol Neurosurg Psychiatry [Internet]. 2020 [cited 2025 Sep 24];91:254\u201362. https:\/\/doi.org\/10.1136\/JNNP-2019-322168.","DOI":"10.1136\/JNNP-2019-322168"},{"key":"640_CR42","doi-asserted-by":"publisher","unstructured":"Pandolfo M, Reetz K, Darling A, Rodriguez De Rivera FJ, Henry PG, Joers J, et al. Efficacy and safety of leriglitazone in patients with Friedreich ataxia: a phase 2 double-blind, randomized controlled trial (FRAMES). Neurol Genet. 2022;8(6):e200034. https:\/\/doi.org\/10.1212\/NXG.0000000000200034.","DOI":"10.1212\/NXG.0000000000200034"},{"key":"640_CR43","doi-asserted-by":"publisher","unstructured":"Wang H, Norton J, Xu L, DeMartinis N, Sen R, Shah A, et al. Results of a randomized double\u2010blind study evaluating luvadaxistat in adults with Friedreich ataxia. Ann Clin Transl Neurol [Internet]. 2021 [cited 2025 Oct 8];8:1343. https:\/\/doi.org\/10.1002\/ACN3.51373.","DOI":"10.1002\/ACN3.51373"},{"key":"640_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ana.24248","volume":"76","author":"M Pandolfo","year":"2014","unstructured":"Pandolfo M, Arpa J, Delatycki MB, Le Quan Sang KH, Mariotti C, Munnich A, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol. 2014;76:509\u201321. https:\/\/doi.org\/10.1002\/ana.24248.","journal-title":"Ann Neurol"},{"key":"640_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.86.16_supplement.p5.388","author":"K Sullivan","year":"2016","unstructured":"Sullivan K, Freeman M, Shaw J, Gooch C, Huang Y, Klein M, et al. EPI-743 for Friedreichs ataxia patients with point mutations (P5.388). Neurology. 2016. https:\/\/doi.org\/10.1212\/wnl.86.16_supplement.p5.388.","journal-title":"Neurology"},{"key":"640_CR46","unstructured":"PTC therapeutics announces topline results from vatiquinone MOVE-FA registration-directed trial | PTC Therapeutics, Inc. https:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-announces-topline-results-vatiquinone-move-fa. Accessed 23 May 2023."},{"key":"640_CR47","doi-asserted-by":"publisher","unstructured":"Lee WJ, Moon J, Jang Y, Shin YW, Son H, Shin S, et al. Nilotinib treatment outcomes in autosomal dominant spinocerebellar ataxia over one year. Sci Rep [Internet]. 2024 [cited 2025 Sep 26];14:1\u201310. https:\/\/doi.org\/10.1038\/S41598-024-67072-Z;SUBJMETA.","DOI":"10.1038\/S41598-024-67072-Z;SUBJMETA"},{"key":"640_CR48","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/archneurol.2010.168","volume":"67","author":"DR Lynch","year":"2010","unstructured":"Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol. 2010;67:941\u20137. https:\/\/doi.org\/10.1001\/archneurol.2010.168.","journal-title":"Arch Neurol"},{"key":"640_CR49","doi-asserted-by":"publisher","unstructured":"Di Prospero NA, Sumner CJ, Penzak SR, Ravina B, Fischbeck KH, Taylor JP. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol [Internet]. 2007 [cited 2025 Sep 26];64:803\u20138. https:\/\/doi.org\/10.1001\/ARCHNEUR.64.6.803.","DOI":"10.1001\/ARCHNEUR.64.6.803"},{"key":"640_CR50","doi-asserted-by":"publisher","unstructured":"Paparella G, Strag\u00e0 C, Pesenti N, Dal Molin V, Martorel GA, Merotto V, et al. A pilot phase 2 randomized trial to evaluate the safety and potential efficacy of etravirine in Friedreich ataxia patients. Children [Internet]. 2024 [cited 2025 Sep 26];11:958. https:\/\/doi.org\/10.3390\/CHILDREN11080958\/S1.","DOI":"10.3390\/CHILDREN11080958\/S1"},{"key":"640_CR51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/mus.26610","volume":"60","author":"M Patel","year":"2019","unstructured":"Patel M, Schadt K, McCormick A, Isaacs C, Dong YN, Lynch DR. Open-label pilot study of oral methylprednisolone for the treatment of patients with Friedreich ataxia. Muscle Nerve. 2019;60:571\u20135. https:\/\/doi.org\/10.1002\/mus.26610.","journal-title":"Muscle Nerve"},{"key":"640_CR52","unstructured":"Acasti announces preliminary topline results met all outcome measures in the pharmacokinetic bridging study for GTX-102, the company\u2019s drug candidate for the treatment of ataxia telangiectasia. https:\/\/www.biospace.com\/acasti-announces-preliminary-topline-results-met-all-outcome-measures-in-the-pharmacokinetic-bridging-study-for-gtx-102-the-company-s-drug-candidate-for-the-treatment-of-ataxia-telangiectasia. Accessed 28 Dec 2022."},{"key":"640_CR53","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/mds.25126","volume":"27","author":"R Zannolli","year":"2012","unstructured":"Zannolli R, Buoni S, Betti G, Salvucci S, Plebani A, Soresina A, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord. 2012;27:1312\u20136. https:\/\/doi.org\/10.1002\/mds.25126.","journal-title":"Mov Disord"},{"key":"640_CR54","doi-asserted-by":"publisher","unstructured":"Zielen S, Crawford T, Benatti L, Magnani M, Kieslich M, Ryan M, et al. Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol [Internet]. 2024 [cited 2025 Oct 9];23:871\u201382. https:\/\/doi.org\/10.1016\/S1474-4422(24)00220-5.","DOI":"10.1016\/S1474-4422(24)00220-5"},{"key":"640_CR55","doi-asserted-by":"publisher","unstructured":"Wang JY, Trivedi AM, Carrillo NR, Yang J, Schneider A, Giulivi C, et al. Open-label allopregnanolone treatment of men with fragile X-associated tremor\/ataxia syndrome. Neurotherapeutics [Internet]. 2017 [cited 2025 Sep 24];14:1073\u201383. https:\/\/doi.org\/10.1007\/S13311-017-0555-6.","DOI":"10.1007\/S13311-017-0555-6"},{"key":"640_CR56","doi-asserted-by":"publisher","unstructured":"Presterud R, Deng WH, Wennerstr\u00f6m AB, Burgers T, Gajera B, Mattsson K, et al. Long-term nicotinamide riboside use improves coordination and eye movements in ataxia telangiectasia. Mov Disord [Internet]. 2024 [cited 2025 Oct 10];39:360\u20139. https:\/\/doi.org\/10.1002\/MDS.29645.","DOI":"10.1002\/MDS.29645"},{"key":"640_CR57","doi-asserted-by":"publisher","unstructured":"Kemp KC, Georgievskaya A, Hares K, Redondo J, Bailey S, Rice CM, et al. An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreich\u2019s ataxia. Nat Commun [Internet]. 2022 [cited 2025 Oct 10];13:1\u20138. https:\/\/doi.org\/10.1038\/S41467-022-31450-W;TECHMETA.","DOI":"10.1038\/S41467-022-31450-W;TECHMETA"},{"key":"640_CR58","doi-asserted-by":"publisher","unstructured":"Rodriguez-Labrada R, Ortega-Sanchez R, Hern\u00e1ndez Casa\u00f1a P, Santos Morales O, Padr\u00f3n-Estupi\u00f1an M del C, Batista-Nu\u00f1ez M, et al. Erythropoietin in spinocerebellar ataxia type 2: feasibility and proof-of-principle issues from a randomized controlled study. Mov Disord [Internet]. 2022 [cited 2025 Oct 10];37:1516\u201325. https:\/\/doi.org\/10.1002\/MDS.29045.","DOI":"10.1002\/MDS.29045"},{"key":"640_CR59","unstructured":"Horizon drops Friedreich\u2019s ataxia therapy actimmune trial program [Internet]. [cited 2025 Sep 26]. https:\/\/friedreichsataxianews.com\/news\/horizon-pharma-scraps-actimmune-clinical-program-fa-friedreichs-ataxia-trial-failure\/?utm_source=chatgpt.com. Accessed 26 Sep 2025."},{"key":"640_CR60","doi-asserted-by":"publisher","unstructured":"Seyer L, Greeley N, Foerster D, Strawser C, Gelbard S, Dong Y, et al. Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol Scand [Internet]. 2015 [cited 2025 Sep 26];132:7\u201315. https:\/\/doi.org\/10.1111\/ANE.12337.","DOI":"10.1111\/ANE.12337"},{"key":"640_CR61","doi-asserted-by":"publisher","unstructured":"Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Ther [Internet]. 2023 [cited 2025 Oct 13];30:738. https:\/\/doi.org\/10.1038\/S41434-023-00390-5.","DOI":"10.1038\/S41434-023-00390-5"},{"key":"640_CR62","doi-asserted-by":"publisher","unstructured":"Dur\u00e3es F, Pinto M, Sousa E. Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals [Internet]. 2018 [cited 2025 Oct 6];11:44. https:\/\/doi.org\/10.3390\/PH11020044.","DOI":"10.3390\/PH11020044"},{"key":"640_CR63","doi-asserted-by":"publisher","unstructured":"Recino A, Rayner MLD, Rohn JL, Della Pasqua O. Therapeutic innovation in drug repurposing: challenges and opportunities. Drug Discov Today [Internet]. 2025 [cited 2025 Oct 13];30:104390. https:\/\/doi.org\/10.1016\/J.DRUDIS.2025.104390.","DOI":"10.1016\/J.DRUDIS.2025.104390"},{"key":"640_CR64","doi-asserted-by":"publisher","unstructured":"Tiet MY, Gu\u021bu BI, Springall-Jeggo P, Coman D, Willemsen M, Van Os N, et al. Biomarkers in ataxia-telangiectasia: a systematic review. J Neurol [Internet]. 2025 [cited 2025 Oct 13];272:1\u201318. https:\/\/doi.org\/10.1007\/S00415-024-12766-7\/FIGURES\/4.","DOI":"10.1007\/S00415-024-12766-7\/FIGURES\/4"},{"key":"640_CR65","doi-asserted-by":"publisher","unstructured":"Shen XN, Wu KM, Huang YY, Guo Y, Huang SY, Zhang YR, et al. Systematic assessment of plasma biomarkers in spinocerebellar ataxia. Neurobiol Dis [Internet]. 2023 [cited 2025 Oct 13];181:106112. https:\/\/doi.org\/10.1016\/J.NBD.2023.106112.","DOI":"10.1016\/J.NBD.2023.106112"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00640-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:01:30Z","timestamp":1792742490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00640-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":65,"alternative-id":["640"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00640-y","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"1 October 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the absence of potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MC: Data collection and analysis, material preparation, and writing\u2014original draft. PP and EL: Visualization, conceptualization, and writing\u2014review and editing. All the other authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":2,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative artificial intelligence (AI) tools were used as an auxiliary support during data organization and therapeutic categorization, and for language editing. No AI-generated content was used directly in the manuscript. All data extraction, classification decisions, interpretation of findings, and manuscript preparation were performed and verified by the authors, who take full responsibility for the content of the article.","order":8,"name":"Ethics","label":"Artificial Intelligence Use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}